Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

Open access

Abstract

Deviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prevalence of homeostatic bacteria such as Akkermansia muciniphila (Akk), while determination of the serum addressin MAdCAM-1 instructs on endothelial gut barrier dysfunction. Here we examined patient survival during chemo-immuno-therapy in 955 cancer patients across four independent cohorts of non-small cell lung (NSCLC), genitourinary (GU) and colorectal (CRC) cancers, according to hallmarks of gut dysbiosis. We show that Akk prevalence represents a stable and favorable phenotype in NSCLC and CRC cancer patients. Over-dominance of Akk above the healthy threshold was observed in dismal prognosis in NSCLC and GU and mirrored an immunosuppressive gut ecosystem and excessive intestinal epithelial exfoliation in NSCLC. In CRC, the combination of a lack of Akk and low sMAdCAM-1 levels identified a subset comprising 28% of patients with reduced survival, independent of the immunoscore. We conclude that gut dysbiosis hallmarks deserve integration within the diagnosis toolbox in oncological practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2025.2484880

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Prevalence of Akkermansia spp. in cancer patients and matched healthy volunteers (HV). a. Stool prevalence of Akk9226 (left) and 9228 (right) in cancer patients and sex and age matched French HV. b. Sankey diagram showing Akk prevalence (either 9226 and/or Akk9228) prevalence over time in paired specimens from 141 NSCLC patients followed longitudinally.
Figure 1. Prevalence of Akkermansia spp. in cancer patients and matched healthy volunteers (HV). a. Stool prevalence of Akk9226 (left) and 9228 (right) in cancer patients and sex and age matched French HV. b. Sankey diagram showing Akk prevalence (either 9226 and/or Akk9228) prevalence over time in paired specimens from 141 NSCLC patients followed longitudinally.CC BY-NC · PubMed Central
Figure 2. Prevalence of Akk9226 is associated with clinical benefit to therapies in NSCLC and CRC. Kaplan-Meier curves and Cox regression analyses of OS. A. NSCLC n = 556 by Akk9226 prevalence (left), 1st L of treatment (middle), 2nd line (right). See Table S3A for multivariable analyses. B. CRC n = 172 by Akk9226 status (left); chemotherapy n = 56 (middle), chemo-immunotherapy n = 116 (right). C. GU n = 215, including UC (n = 133, middle), RCC (n = 82, right), by Akk9226 status. Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox regression analyses. The conclusions were similar in the multivariable (also refer to Table S3A) p = 0.071).
Figure 2. Prevalence of Akk9226 is associated with clinical benefit to therapies in NSCLC and CRC. Kaplan-Meier curves and Cox regression analyses of OS. A. NSCLC n = 556 by Akk9226 prevalence (left), 1st L of treatment (middle), 2nd line (right). See Table S3A for multivariable analyses. B. CRC n = 172 by Akk9226 status (left); chemotherapy n = 56 (middle), chemo-immunotherapy n = 116 (right). C. GU n = 215, including UC (n = 133, middle), RCC (n = 82, right), by Akk9226 status. Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox regression analyses. The conclusions were similar in the multivariable (also refer to Table S3A) p = 0.071).CC BY-NC · PubMed Central
Figure 3. Low levels of Akk9226 are associated with favorable prognosis in NSCLC. A. Distribution of Akk9226 relative abundance in NSCLC patients: Akk9226Neg (undetectable), Akk9226Low (0–4.799%), Akk9226High (>4.799%). B-C. Kaplan-Meier curves and Cox model for OS (B) and PFS (C) in 556 NSCLC patients by Akk9226 status. D-E. Same for 1st L (D) and 2nd L (E) ICI in NSCLC. Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses. The conclusions were similar in the multivariable (also refer to Table S3B, p = 0.014 vs Akk9226 neg and p = 0.007 vs Akk9226 high).
Figure 3. Low levels of Akk9226 are associated with favorable prognosis in NSCLC. A. Distribution of Akk9226 relative abundance in NSCLC patients: Akk9226Neg (undetectable), Akk9226Low (0–4.799%), Akk9226High (>4.799%). B-C. Kaplan-Meier curves and Cox model for OS (B) and PFS (C) in 556 NSCLC patients by Akk9226 status. D-E. Same for 1st L (D) and 2nd L (E) ICI in NSCLC. Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses. The conclusions were similar in the multivariable (also refer to Table S3B, p = 0.014 vs Akk9226 neg and p = 0.007 vs Akk9226 high).CC BY-NC · PubMed Central
Figure 4. High Akk9226 relative abundance is a surrogate hallmark of gut dysbiosis and epithelial exfoliation. A. PCoA of fecal taxonomic composition (inset), Shannon and richness indices and VIP score for Akk9226Neg versus Akk9226Low (left) and Akk9226Low versus Akk9226High (right). ANOSIM and PERMANOVA assess group separation significance after 999 permutations. PLS-DA and VIP identify key microbial species by importance with bar color depicting the cohort with the highest mean relative abundance. Mann-Whitney test for significance (*p < 0.05, **p < 0.01, ***p < 0.001). B. Kernel density plot of the exfoliated human reads (Log10 scale) in three Akk9226 groups according to lines of therapy in NSCLC and significance between medians was computed with Kruskal-Wallis’s test and Dunn’s test.
Figure 4. High Akk9226 relative abundance is a surrogate hallmark of gut dysbiosis and epithelial exfoliation. A. PCoA of fecal taxonomic composition (inset), Shannon and richness indices and VIP score for Akk9226Neg versus Akk9226Low (left) and Akk9226Low versus Akk9226High (right). ANOSIM and PERMANOVA assess group separation significance after 999 permutations. PLS-DA and VIP identify key microbial species by importance with bar color depicting the cohort with the highest mean relative abundance. Mann-Whitney test for significance (*p < 0.05, **p < 0.01, ***p < 0.001). B. Kernel density plot of the exfoliated human reads (Log10 scale) in three Akk9226 groups according to lines of therapy in NSCLC and significance between medians was computed with Kruskal-Wallis’s test and Dunn’s test.CC BY-NC · PubMed Central
Figure 5. High levels of Akk9226 are associated with dismal prognosis in urinary tract cancers (GU) but not CRC. a distribution of Akk9226 relative abundance in HV, GU and CRC patients: Akk9226Neg (undetectable), Akk9226Low (0–4.799%), Akk9226High (>4.799%). P-value are fisher exact test with FDR correction. b, c. Kaplan-Meier curves and Cox model for OS in 215 GU patients (b) and 172 CRC patients (c) by Akk9226 status (Akk9226Neg, Akk9226Low, and Akk9226High). Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses.
Figure 5. High levels of Akk9226 are associated with dismal prognosis in urinary tract cancers (GU) but not CRC. a distribution of Akk9226 relative abundance in HV, GU and CRC patients: Akk9226Neg (undetectable), Akk9226Low (0–4.799%), Akk9226High (>4.799%). P-value are fisher exact test with FDR correction. b, c. Kaplan-Meier curves and Cox model for OS in 215 GU patients (b) and 172 CRC patients (c) by Akk9226 status (Akk9226Neg, Akk9226Low, and Akk9226High). Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses.CC BY-NC · PubMed Central
Figure 6. Interaction between sMadCAM-1 and Akk9226 as a prognostic signature in CRC. a. Plasma sMadCAM-1 levels by treatment arm in CRC. Each dot is one patient/plasma. b-c. Kaplan-Meier curves and multivariable Cox model for OS in CRC n = 162, in chemotherapy n = 54 (C, left) and in chemo-immunotherapy n = 108 (C, right) by sMadCAM-1 levels according to the cohort median (Low≤s138.4803 ng.mL−1). d-e. Kaplan-Meier curves and Cox model for PFS (D) and OS (E) in 150 patients with paired stool and plasma samples according to sMadCAM-1 levels and Akk9226 prevalence (sMAdCAM-1Low or High, Akk9226Pos or Akk9226Neg). Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses.
Figure 6. Interaction between sMadCAM-1 and Akk9226 as a prognostic signature in CRC. a. Plasma sMadCAM-1 levels by treatment arm in CRC. Each dot is one patient/plasma. b-c. Kaplan-Meier curves and multivariable Cox model for OS in CRC n = 162, in chemotherapy n = 54 (C, left) and in chemo-immunotherapy n = 108 (C, right) by sMadCAM-1 levels according to the cohort median (Low≤s138.4803 ng.mL−1). d-e. Kaplan-Meier curves and Cox model for PFS (D) and OS (E) in 150 patients with paired stool and plasma samples according to sMadCAM-1 levels and Akk9226 prevalence (sMAdCAM-1Low or High, Akk9226Pos or Akk9226Neg). Between groups, survival comparisons were performed using the two-sided log-rank test. The hazard ratios correspond to the related univariable Cox analyses.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 1

  1. 10.1158/2159-8290.CD-21-0999 · DOI · Paper page

Cited by

See all 21

Metadata

Authors
Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., Routy, B., Fidelle, M., Zalcman, G., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., Scherpereel, A., Pegliasco, H., Ghiringhelli, F., Reni, A., Barlesi, F., Albiges, L., Planchard, D., Martinez, S., Besse, B., Segata, N., Cremolini, C., Zitvogel, L., Iebba, V., & Derosa, L.
Affiliations
  • Inserm (FR)
  • Université Paris-Saclay (FR)
  • Gustave Roussy Cancer Campus, ClinicObiome
  • University of Pisa (IT)
  • University of Trento (IT)
  • University of Verona (IT)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Bichat-Claude Bernard Hospital, AP-HP, Université Paris Cité
  • Centre Hospitalier Universitaire de Toulouse
  • Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer (FR)
  • Centre Hospitalier Universitaire
  • Université Paris Cité (FR)
  • European Hospital (IT)
  • Centre Hospitalier Intercommunal Aix-Pertuis (FR)
  • Institut Gustave Roussy (FR)
Corresponding author
Derosa, Lisa
Venue
OncoImmunology
Published
2025-04-06
Volume
14
Issue
1
Pages
2484880-2484880
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W4409204557
Cited by
21
References
58
Citations by year
2026: 15 · 2025: 6
FWCI
6.31
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Iris (University of Trento) (submittedVersion, cc-by-nc)
Funders
European Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut dysbiosis, Akkermansia muciniphila, MAdCAM-1, intestinal barrier dysfunction, cancer survival, non-small cell lung cancer, colorectal cancer, genitourinary cancer, immune score, immunosuppression, prognostic factors, gut microbiota
MeSH terms
Gastrointestinal Microbiome, Akkermansia, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Prognosis, Urogenital Neoplasms, Colorectal Neoplasms, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. https://app.cochat.ai/papers/10.1080/2162402x.2025.2484880
The paper
Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., Routy, B., Fidelle, M., Zalcman, G., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., Scherpereel, A., Pegliasco, H., . . . Derosa, L. (2025). Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. OncoImmunology. https://doi.org/10.1080/2162402x.2025.2484880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.